Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 17Dermatologic 5Thoracic 4Gastrointestinal 4Gynecologic 3Genitourinary 2Breast 2Sarcoma 1Lymphoid 1

Conditions

Sarcoma 4Neoplasms 4Neoplasm Metastasis 3Melanoma 3Liposarcoma 2Leiomyosarcoma 2Hemangiosarcoma 2Head and Neck Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Kidney Neoplasms 1Gliosarcoma 1Glioblastoma 1Eyelid Squamous Cell Carcinoma 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 11Nivolumab 4Erlotinib Hydrochloride 3Docetaxel 3Cetuximab 3Capecitabine 3tislelizumab 2spartalizumab 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Gemcitabine 2Filgrastim 2Cyclophosphamide 2tremelimumab 1sargramostim 1ribociclib 1poly ICLC 1pexidartinib 1mirabegron 1futibatinib 1etoposide phosphate 1entinostat 1durvalumab 1ciforadenant 1cemiplimab 1capivasertib 1bempegaldesleukin 1avelumab 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × cemiplimab × Sarcoma × Clear all
NCT05094804 2023-11-02

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

OncoResponse, Inc.

Phase 1/2 Unknown
172 enrolled
DermatologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Leiomyosarcoma, Liposarcoma, Melanoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡